Loading...
XASX
CGS
Market cap403mUSD
Oct 09, Last price  
3.45AUD
1D
1.17%
1Q
18.97%
Jan 2017
184.22%
IPO
608.81%
Name

CogState Ltd

Chart & performance

D1W1MN
XASX:CGS chart
P/E
33.57
P/S
6.82
EPS
0.07
Div yield, %
0.59%
Shrs. gr., 5y
0.49%
Rev. gr., 5y
12.87%
Revenues
60m
+79.84%
2,349,8563,783,4878,387,1859,484,9588,133,25812,014,41112,462,75611,547,84816,073,36927,252,05535,012,76527,508,47221,834,37423,536,33432,686,39644,980,35639,937,07943,427,77333,291,35659,872,113
Net income
12m
+82.89%
-1,402,253-714,2061,153,7861,391,760-904,3942,509,325-1,786,171-3,660,906-3,882,7272,641,919-853,062-537,610-2,439,545-2,022,3275,267,2527,129,5933,522,3953,633,7646,646,62712,156,296
CFO
10m
-15.55%
-1,353,744-704,537914,5751,491,838622,7031,420,223-1,627,592-3,409,015-2,776,9252,550,7913,242,491-75,034425,271770,21816,114,4109,726,133654,1295,782,52611,475,2009,691,160
Dividend
Aug 21, 20260.04 AUD/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Cogstate Limited, a neuroscience technology firm established in 1999 and headquartered in Melbourne, Australia, specializes in digital cognitive assessments and electronic solutions for evaluating clinical outcomes. The company offers a comprehensive suite of cognitive services, encompassing project and data management, scientific consulting, statistical interpretation, acquisition of assessment tools, rater training, and monitoring solutions. It operates through two primary divisions: Clinical Trials and Healthcare. The Clinical Trials segment delivers specialized technology and related support to pharmaceutical and biotechnology companies, enabling them to precisely measure the impact of diseases, medications, medical devices, or other interventions on human participants in clinical studies. Conversely, its Healthcare division supplies Cognigram, a standardized and routine testing system designed to assist primary care providers and hospitals in the early identification of cognitive impairment. As of June 30, 2022, Cogstate had contributed to approximately 1,800 academic research endeavors.

Key people

Martyn Myer
Non-Executive Chairman of the Board
Darren Watson
Chief Financial Officer · since 2021
Rachel Colite
Executive Vice President - Clinical Trials · since 2023
Chris Edgar
Chief Scientific Officer · since 2022
Brad O'Connor
Chief Executive Officer, Managing Director, Executive Director · since 2005
Kaycee Sink
Chief Medical Officer · since 2024
Company Secretary · since 2022
Kristi Geddes
General Counsel, Joint Company Secretary · since 2023
Richard Mohs
Independent Non-Executive Director · since 2021
Independent Non-Executive Director · since 2019
Kim Wenn
Independent Non-Executive Director · since 2020
IPO date
Feb 13, 2004
Employees
172
Domiciled in
AU
Incorporated in
AU
Headquarters & legal address
LEVEL 2
161 COLLINS ST
MELBOURNE, VIC 3000
AU
Previous name
EXAMINATION SERVICES FOR PSYCHOLOGY LIMITED

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2026‑062025‑062024‑062023‑062022‑062021‑062020‑062019‑062018‑062017‑06
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT